| Title |
Cost-Effectiveness Analysis of Vedolizumab Compared with Other Biologics in Anti-TNF-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan
|
|---|---|
| Published in |
PharmacoEconomics, September 2019
|
| DOI | 10.1007/s40273-019-00841-1 |
| Pubmed ID | |
| Authors |
Luis Hernandez, Hiroyo Kuwabara, Anshul Shah, Kaoru Yamabe, Heather Burnett, Kyle Fahrbach, Maria Koufopoulou, Ryuichi Iwakiri |
X Demographics
The data shown below were collected from the profiles of 5 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 40% |
| New Zealand | 1 | 20% |
| Unknown | 2 | 40% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 4 | 80% |
| Science communicators (journalists, bloggers, editors) | 1 | 20% |
Mendeley readers
The data shown below were compiled from readership statistics for 79 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 79 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 10 | 13% |
| Student > Bachelor | 9 | 11% |
| Unspecified | 8 | 10% |
| Student > Master | 8 | 10% |
| Student > Doctoral Student | 6 | 8% |
| Other | 15 | 19% |
| Unknown | 23 | 29% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 17 | 22% |
| Pharmacology, Toxicology and Pharmaceutical Science | 9 | 11% |
| Unspecified | 8 | 10% |
| Economics, Econometrics and Finance | 4 | 5% |
| Nursing and Health Professions | 3 | 4% |
| Other | 13 | 16% |
| Unknown | 25 | 32% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 26 September 2019.
All research outputs
#7,409,087
of 23,511,526 outputs
Outputs from PharmacoEconomics
#856
of 1,875 outputs
Outputs of similar age
#130,399
of 346,785 outputs
Outputs of similar age from PharmacoEconomics
#13
of 24 outputs
Altmetric has tracked 23,511,526 research outputs across all sources so far. This one has received more attention than most of these and is in the 68th percentile.
So far Altmetric has tracked 1,875 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.0. This one has gotten more attention than average, scoring higher than 53% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 346,785 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 61% of its contemporaries.
We're also able to compare this research output to 24 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 50% of its contemporaries.